The University of Colorado and UCHealth are recruiting potential candidates for a COVID-19 vaccine Phase III trial for NVX-CoV2373.

NovaVax’s vaccine candidate uses deactivated pieces of the COVID-19 protein and an immune system booster to build immunity. The currently-approved vaccines from Pfizer Inc. (NYSE: PFE) and Moderna Inc. (Nasdaq: MDNA) use messenger RNA to produce spike proteins of the virus within a patient’s cells, which are then identified by the immune system and…

… Continue Reading at: www.dailycamera.com [source]